These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 19923873

  • 1. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options.
    Tillement JP, Lecanu L, Papadopoulos V.
    Pharmacology; 2010; 85(1):1-17. PubMed ID: 19923873
    [Abstract] [Full Text] [Related]

  • 2. Drug targets for amyloidosis.
    Kolstoe SE, Wood SP.
    Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
    [Abstract] [Full Text] [Related]

  • 3. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
    Naiki H, Nagai Y.
    J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812
    [Abstract] [Full Text] [Related]

  • 4. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM, Fischer DF, Ovaa H, Scheper W.
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [Abstract] [Full Text] [Related]

  • 5. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M, Andrisano V.
    Chembiochem; 2010 May 17; 11(8):1018-35. PubMed ID: 20401887
    [Abstract] [Full Text] [Related]

  • 6. Membrane permeabilization: a common mechanism in protein-misfolding diseases.
    Lashuel HA.
    Sci Aging Knowledge Environ; 2005 Sep 21; 2005(38):pe28. PubMed ID: 16186179
    [Abstract] [Full Text] [Related]

  • 7. Protein misfolding and neurodegeneration.
    Soto C, Estrada LD.
    Arch Neurol; 2008 Feb 21; 65(2):184-9. PubMed ID: 18268186
    [Abstract] [Full Text] [Related]

  • 8. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
    Waldmeier PC, Tatton WG.
    Drug Discov Today; 2004 Mar 01; 9(5):210-8. PubMed ID: 14980539
    [Abstract] [Full Text] [Related]

  • 9. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K, Robotka H, Toldi J, Vécsei L.
    J Neurol Sci; 2007 Jun 15; 257(1-2):221-39. PubMed ID: 17462670
    [Abstract] [Full Text] [Related]

  • 10. Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis.
    Kourie JI, Culverson AL, Farrelly PV, Henry CL, Laohachai KN.
    Cell Biochem Biophys; 2002 Jun 15; 36(2-3):191-207. PubMed ID: 12139405
    [Abstract] [Full Text] [Related]

  • 11. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA.
    J Neurol Sci; 2005 Jun 15; 233(1-2):145-62. PubMed ID: 15896810
    [Abstract] [Full Text] [Related]

  • 12. The role of autophagy in age-related neurodegeneration.
    McCray BA, Taylor JP.
    Neurosignals; 2008 Jun 15; 16(1):75-84. PubMed ID: 18097162
    [Abstract] [Full Text] [Related]

  • 13. Protein homeostasis in neurons and its pathological alterations.
    Malgaroli A, Vallar L, Zimarino V.
    Curr Opin Neurobiol; 2006 Jun 15; 16(3):270-4. PubMed ID: 16713705
    [Abstract] [Full Text] [Related]

  • 14. [Conformational and intermolecular interactions of proteins in amyloidosis].
    Mal'tsev AV, Kaminskiĭ IuG, Il'iasov FE, Rozanova NA, Fediukin VS, Baĭramov VM.
    Biofizika; 2005 Jun 15; 50(3):470-4. PubMed ID: 15977837
    [Abstract] [Full Text] [Related]

  • 15. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B.
    IDrugs; 2009 Jun 15; 12(6):349-52. PubMed ID: 19517313
    [No Abstract] [Full Text] [Related]

  • 16. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
    Mandel S, Youdim MB.
    Free Radic Biol Med; 2004 Aug 01; 37(3):304-17. PubMed ID: 15223064
    [Abstract] [Full Text] [Related]

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 18. Roles of extracellular chaperones in amyloidosis.
    Wyatt AR, Yerbury JJ, Dabbs RA, Wilson MR.
    J Mol Biol; 2012 Aug 24; 421(4-5):499-516. PubMed ID: 22248589
    [Abstract] [Full Text] [Related]

  • 19. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK, Paul S.
    FEBS J; 2006 Apr 24; 273(7):1331-49. PubMed ID: 16689923
    [Abstract] [Full Text] [Related]

  • 20. [Proteins and mutations: a new vision (molecular) of neurodegenerative diseases].
    Christen Y.
    J Soc Biol; 2002 Apr 24; 196(1):85-94. PubMed ID: 12134639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.